Roflumilast , a first-in-class , potent and selective phosphodiesterase 4 ( PDE4 ) inhibitor , reduces the rate of exacerbations in patients with a high risk of future exacerbations and has been shown to reduce inflammatory cells and mediators in induced sputum , a surrogate of airway inflammation .